Sareum Holdings PLC Notice of AGM and Annual Report & Accounts (8386W)

TIDMSAR

RNS Number : 8386W

Sareum Holdings PLC

20 November 2017

 
 (AIM: SAR)   20 November 2017 
 

Sareum Holdings plc

("Sareum" or "the Company")

Notice of AGM and Annual Report & Accounts

Sareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business, has notified its shareholders that its Annual General Meeting ("AGM") will take place at 10.00 a.m. on 14 December 2017 at the offices of Citigate Dewe Rogerson, 3 London Wall Buildings, London Wall, London EC2M 5SY.

On 17 November 2017, the Company Annual Report and Accounts for the year ended 30 June 2017 was posted to shareholders who requested a hard copy and the notice convening the 2017 AGM was posted to all shareholders. A copy of both documents has been placed on the Company website.

For further information, please contact:

 
Sareum Holdings plc 
Tim Mitchell                           01223 497 700 
WH Ireland Limited (Nominated Adviser and 
 Co-Broker) 
Chris Fielding / James Sinclair-Ford   020 7220 1666 
Hybridan LLP (Co-Broker) 
Claire Noyce                           020 3764 2341 
Citigate Dewe Rogerson (Media 
 enquiries) 
Shabnam Bashir/ Mark Swallow/ 
 David Dible                           020 7282 9571 
 

Notes for editors:

Sareum is a specialist drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, and generating value through licensing them to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Its most advanced programme, SRA737, is a novel Checkpoint kinase 1 (Chk1) inhibitor licensed to NASDAQ-listed Sierra Oncology and in clinical trials targeting a range of advanced cancers. The key role of Chk1 in cancer cell replication and DNA damage repair suggests that SRA737 may have broad application as a targeted therapy in combination with other oncology and immune-oncology drugs in genetically defined patients.

Sareum is also advancing programmes to develop novel tyrosine kinase 2 (TYK2) inhibitors in autoimmune diseases and cancers, and Aurora+FLT3 inhibitors in haematological cancers, which are in the IND-enabling preclinical and lead optimisation stages.

The Company's drug discovery technology platform (SKIL(R) - Sareum Kinase Inhibitor Library) is being applied to generate drug research programmes against other kinase targets.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit www.sareum.co.uk

- Ends -

This information is provided by RNS

The company news service from the London Stock Exchange

END

NOAUBUARBOAAAAA

(END) Dow Jones Newswires

November 20, 2017 02:01 ET (07:01 GMT)